A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | MicrobiomeTrials← Back to trialsNCT06045754
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2024-04-18Est. Completion: 2027-06-28
Enrollment target: 50 participants Locations- Digestive Health Specialsits, Dothan, Alabama, United States
- GI Alliance Sun City, Sun City, Arizona, United States
- University of California San Diego Health (UCSD), La Jolla, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Hoag Hospital Newport Beach, Newport Beach, California, United States
- Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States
- Clinical Research of Osceola, Kissimmee, Florida, United States
- Endoscopic Research Inc, Orlando, Florida, United States
- Alliance Clinical Research of Tampa, LLC, Tampa, Florida, United States
- Gastroenterology Consultants, P.C., Roswell, Georgia, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Cotton ONeil Clinical Research Center, Topeka, Kansas, United States
- University of Louisville, Louisville, Kentucky, United States
- GI Alliance, Metairie, Louisiana, United States
- Tulane University, New Orleans, Louisiana, United States
Other microbiome trials you might be interested in
Inflammatory Bowel Diseases (IBD)Crohn DiseaseColitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple LocationsEst. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, ChinaCompleted Mar 30, 2026
Huron Gastroenterology Associates, P.C., Ypsilanti, Michigan, United StatesMid-America Gastro-Intestinal Consultants, Kansas City, Missouri, United StatesBVL Clinical Research, Liberty, Missouri, United StatesWashington University School of Medicine, St Louis, Missouri, United StatesNYU Langone Health, New York, New York, United StatesUniversity of Cincinnati, Cincinnati, Ohio, United StatesOhio Gastroenterology group, Inc., Columbus, Ohio, United StatesGreat Lakes Gastroenterology Research, LLC, Mentor, Ohio, United StatesGastro Intestinal Research Institute of Northern Ohio, LLC., Westlake, Ohio, United StatesDigestive Disease Specialists, Inc., Oklahoma City, Oklahoma, United StatesAllegheny Health Network, Wexford, Pennsylvania, United StatesUniversity Gastroenterology, Providence, Rhode Island, United StatesSanford Health Research, Rapid City, South Dakota, United StatesTexas Digestive Disease Consultants Cedar Park, Cedar Park, Texas, United StatesGI Alliance - Digestive Health Associates of Texas, Dallas, Texas, United StatesThe University of Texas Health Science Center at Houston, Houston, Texas, United StatesTexas Digestive Disease Consultants Lubbock, Lubbock, Texas, United StatesGI Alliance - Mansfield, Mansfield, Texas, United StatesGastroenterology Research of San Antonio, LLC, San Antonio, Texas, United StatesSouthern Star Research Institute, LLC., San Antonio, Texas, United StatesTexas Digestive Disease Consultants (TDDC), Southlake, Southlake, Texas, United StatesTyler Research Institute, LLC, Tyler, Texas, United StatesGI Alliance - Webster, Webster, Texas, United StatesUniversity of Utah Health, Salt Lake City, Utah, United StatesWashington Gastroenterology- GIA, Tacoma, Washington, United StatesCovenant Health, Edmonton, Alberta, CanadaLondon Health Sciences Centre, London, Ontario, CanadaViable Clinical Research - North Bay, North Bay, Ontario, CanadaToronto Immune and Digestive Health Institute Inc. (TIDHI), North York, Ontario, CanadaABP Research Services Corp., Oakville, Ontario, CanadaToronto Digestive Disease Associates (TDDA) Inc., Vaughan, Ontario, CanadaThe Research Institute of the McGill University Health Centre, Montreal, Quebec, CanadaPhase 4
Recruiting
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 pa…
Miami, United StatesEst. completion Sep 1, 2027